# Todd Dickinson

> Todd Dickinson is the CEO and a board member of Stellaromics, a Boston biotech commercializing 3D spatial biology born from Karl Deisseroth's Stanford lab and Xiao Wang's work at MIT and the Broad Institute. A Tufts-trained analytical chemist who did his PhD under David Walt, he spent more than 20 years turning genomics inventions into products: over a decade at Illumina during its rise as the DNA-sequencing leader, commercial work on Bionano Genomics' Irys nanochannel arrays, and CEO stints at Dovetail Genomics and Arc Bio, which he merged into Cantata Bio in 2022. At Stellaromics he raised $80 million in Series B (led by Catalyst4 with Stanford University Ventures) to launch Pyxa, the first commercial platform that reads gene expression inside intact tissue up to 40x thicker than conventional methods.

- **Role:** Chief Executive Officer & Board Member at Stellaromics Inc.
- **Organizations:** Stellaromics Inc., Cantata Bio, Dovetail Genomics, Arc Bio, Bionano Genomics, Illumina
- **Nationality:** American
- **Education:** Dual degrees in Chemistry and Theology, St. Olaf College, Ph.D. in Analytical Chemistry (advisor: Prof. David Walt), Tufts University
- **Known for:** Raised $105 million total for Stellaromics across Series A ($25M) and Series B ($80M), Launched Pyxa, described as the first commercially available platform for multiplexed 3D spatial transcriptomics in intact tissue, Merged Dovetail Genomics and Arc Bio into Cantata Bio in 2022

## Career timeline

- **early career** — Joined Illumina during its rise as the global leader in DNA sequencing; spent over a decade there in technical and commercial executive roles
- **mid career** — Led development and commercialization of Bionano Genomics' Irys nanochannel array product
- **pre-2022** — Served as CEO of Dovetail Genomics and CEO of Arc Bio
- **2022** — Merged Dovetail Genomics and Arc Bio into Cantata Bio, serving as CEO
- **2022** — Stellaromics founded, spun out of Karl Deisseroth's Stanford lab and Xiao Wang's MIT/Broad Institute lab
- **2023** — Appointed President & CEO of Stellaromics; company closes $25M Series A led by Plaisance Capital Management
- **2025** — Raised $80M Series B led by Catalyst4 with Stanford University Ventures; unveiled the Pyxa platform at AGBT
- **2025** — Pyxa early-access program fully subscribed; commercial shipments slated for end of 2025

## Achievements

- Raised $105 million total for Stellaromics across Series A ($25M) and Series B ($80M)
- Launched Pyxa, described as the first commercially available platform for multiplexed 3D spatial transcriptomics in intact tissue
- Merged Dovetail Genomics and Arc Bio into Cantata Bio in 2022
- Part of Illumina's rise as the global leader in DNA sequencing
- Led commercialization of Bionano Genomics' Irys nanochannel array system
- Grew Stellaromics to roughly 58 employees

## Latest updates

- **2025-02** — Stellaromics raised $80M Series B led by Catalyst4 with Stanford University Ventures and unveiled the Pyxa platform at AGBT
- **2025-06** — Pyxa early-access program fully subscribed; commercial shipments slated for end of 2025

## Links

- Website: https://stellaromics.com
- LinkedIn: http://www.linkedin.com/in/todd-dickinson-2296b822

---

Profile page: https://yespress.io/todd-dickinson
Published by YesPress — https://yespress.io
Last updated: 2026-07-08